ACADIA PHARMACEUTICALS INC. Payments to Acquire Available-for-sale Securities, Equity
ACADIA PHARMACEUTICALS INC. (ACAD) reported Payments to Acquire Available-for-sale Securities, Equity of $3.15 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-25.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesEquity · last filed 2021-02-25
- ACADIA PHARMACEUTICALS INC. payments to acquire available-for-sale securities, equity for the quarter ending 2018-12-31 was -$1.00K.
- ACADIA PHARMACEUTICALS INC. payments to acquire available-for-sale securities, equity for the quarter ending 2018-09-30 was $0.00.
- ACADIA PHARMACEUTICALS INC. payments to acquire available-for-sale securities, equity for fiscal 2018 was $3.15M.
| Period end | Payments to Acquire Available-for-sale Securities, Equity 3 month | Payments to Acquire Available-for-sale Securities, Equity 6 month | Payments to Acquire Available-for-sale Securities, Equity 9 month | Payments to Acquire Available-for-sale Securities, Equity 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$1.00K derived: sum of 2 quarters · filed 2021-02-25 | $3.15M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $3.15M 10-Q · filed 2019-10-31 | ||
| 2018-06-30 | $3.15M 10-Q · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |